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The unfailing detection of micrometastases during surgery of patients suffering from ovarian cancer is mandatory for the optimal
management of this disease. Thus, the present study aimed at determining the feasibility of detecting micrometastases in an ovarian
cancer model using the intraperitoneal administration of the photosensitiser precursor hexaminolaevulinate (HAL). For this purpose,
HAL was applied intraperitoneally at different concentrations (4–12mM) to immunocompetent Fischer 344 rats bearing a syngeneic
epithelial ovarian carcinoma. The tumours were visualised laparoscopically using both white and blue light (D-light, Karl Storz,
Tuttlingen, Germany), and the number of peritoneal micrometastases detected through HAL-induced photodiagnosis (PD) was
compared to standard white light visualisation. Fluorescence spectra were recorded with an optical fibre-based spectrofluorometer
and the fluorescence intensities were compared to the protoporphyrin IX (PpIX) fluorescence induced by 5-aminolevulinic acid
under similar conditions. The number of metastases detected by the PD blue light mode was higher than when using standard white
light abdominal inspection for all applied concentrations. Twice as many cancer lesions were detected by fluorescence than by white
light inspection. The hexyl-ester derivative produced higher PpIX fluorescence than its parent substance aminolevulinic acid at the
same concentration and application time. Fluorescence contrast between healthy and cancerous tissue was excellent for both
compounds. To overcome poor diagnostic efficiency and to detect peritoneal ovarian carcinoma foci in the large surface area of the
human peritoneal cavity, HAL fluorescence-based visualisation techniques may acquire importance in future and lead to a more
correct staging of early ovarian cancer.
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Only ovarian cancer patients who have undergone a thorough
surgical staging procedure, with early-stage and well or moderately
differentiated tumours, may be considered as cured by surgery
alone, and therefore do not require adjuvant therapy (Trimbos
et al, 1991). Occult extra-ovarian metastases are found in about
15–20% of patients initially diagnosed as early ovarian cancer
confined to the ovary. The confirmed absence of such micro-
metatstatic lesions in the peritoneal cavity does have impact on the
decision-making process of the physician with respect to the
treatment regimen as well as on patient’s quality of life.
Statistically, these occult lesions are found in the diaphragm
(7%), the omentum (5%), peritoneal biopsy specimens (10%), and
peritoneal cytology (20%) (Leblanc et al, 2000).
The magnitude of the problem becomes even more apparent
following optimally performed re-staging operations. Up to 30% of
patients with presumed early-stage ovarian cancer will be upstaged
if re-explored, and approximately two-thirds of these patients will
have stage III disease (Bagley Jr et al, 1973; Piver, 1982; Young et al,
1983; Helewa et al, 1986; Buchsbaum et al, 1989; Soper et al, 1992).
Despite attempts at improving staging through computed tomo-
graphy (CT), magnetic resonance imaging (MRI), and other
established imaging diagnostic tools, the detection of residual
micrometastatic disease remains a challenge to the gynaecological
oncologist and collaborating disciplines.
To overcome poor diagnostic efficiency in the large surface area
of the human peritoneal cavity, fluorescence-based visualisation
techniques might acquire greater importance in the future.
Fluorescence photodetection (PD) takes advantage of the optical
properties of the tissues, either inherent (autofluorescence) or
induced by exogenously administered photoactive compounds.
The fact that cancerous tissue often shows differences not only in
its biological behaviour, but also in the resulting optical
characteristics has allowed PD of malignant disease in fields such
as urology, (Jichlinski et al, 1997a,b; Kriegmair et al, 1999)
dermatology (Orenstein et al, 1997) and pulmology (Monnier Ph
et al, 1990).
Although not a photoactive compound itself, exogenously
administered 5-aminolaevulinic acid (ALA), the first committed
intermediate in the haeme biosynthetic pathway, results in a
temporary accumulation of fluorescing porphyrin precursors,
particularly protoporphyrin IX (PpIX). Administration of exogen-
ous ALA bypasses the negative feedback control and induces the
preferential accumulation of PpIX in malignant cells of epithelial
origin (for a review, see Peng et al, 1997) The fluorescence of PpIX
can easily be used for diagnostic purposes when excited by light
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swith in the blue range of the visible spectrum (Wagnieres et al,
1998). In many medical areas, ALA-induced PD has replaced the
photosensitiser compounds used previously, because of its simple
application scheme (systemic or topical), almost complete absence
of side effects, short-lasting phototoxicity, and good discrimina-
tion between malignant and nonmalignant tissue (Peng et al,
1997).
We were previously able to show in a preclinical and clinical
setting that ALA-induced PD can successfully make visible ovarian
cancer micrometastases in the peritoneal cavity (Major et al, 1997,
2002a,b; Hornung et al, 1998). While ALA-induced PD has proven
its feasibility in detecting ovarian cancer micrometastases, the
pharmacological properties of ALA make it suboptimal when
applied topically or, as in our research, intraperitoneally in ovarian
cancer patients. 5-Aminolaevulinic acid is a hydrophilic molecule,
and its penetration across biological membranes is partially
compromised. 5-Aminolaevulinic acid-induced PpIX formation
after topical application shows considerable heterogeneity and the
depth of penetration is limited (Lange et al, 1999, 2001). More
lipophilic derivatives of ALA are currently under clinical assess-
ment, in attempts to enhance ALA’s poor bioavailability. It has
been shown that the hexyl-ester derivative of ALA (hexaminolae-
vulinate (HLA)) represents a good compromise between aqueous
solubility and lipophilicity.
Our aim was to determine the feasibility of detecting micro-
metastases in an ovarian cancer model using the intraperitoneal
administration of the photosensitiser precursor HAL. Additionally,
we aimed to quantify the peritoneal micrometastases through
HAL-induced PD, and to compare the number of detected lesions
with the one obtained through standard white light visualisation.
MATERIALS AND METHODS
Female Fischer (F-344) rats (120–160g) were housed in a
pathogen-free animal facility at the ‘Fondation pour la recherche
me ´dicale’, Geneva. They were given unlimited access to commer-
cial basal diet and water. The experimental protocol for the use of
animals for these studies was approved by the Institutional Ethics
Review Board and the local veterinary office. The study was carried
out according to the UKCCCR guidelines for the welfare of animals
in experimental neoplasia (Workman et al, 1998). In particular, it
should be noted that the experimental system was set up so as to
detect ovarian cancer metastases at a very early stage of the disease
when implants are not or only difficult to visualise with the naked
eye. In our system, this was the case after 5 weeks of tumour
induction.
The NuTu-19 cell line is a poorly differentiated Fischer 344 rat-
derived epithelial ovarian cancer cell line (Rose et al, 1996). Cells
were cultured in DMEM medium (Gibco Life Technologies,
Carlsbad, USA) enriched with 10% foetal calf serum (Gibco Life
Technologies), penicillin 25IEml
 1, streptomycin 25mgml
 1, and
incubated under standardised conditions (371C, 7% carbon
dioxide, 100% humidity). One million cells per animal were
harvested with 0.25% trypsin (Gibco Life Technologies), washed
with phosphate-buffered saline (PBS) (Gibco Life Technologies)
and injected intraperitoneally.
At 5 weeks after tumour induction, crystallised ALA hydro-
chloride (Merck, Darmstadt, Germany) was diluted in PBS and
titrated with NaOH to pH 7.4. The synthesis of HAL is described
elsewhere (Kloek et al, 1998; Lange et al, 1999). In all, 2ml of
solution (4–12mM HAL in PBS titrated with HCl to pH 7.4, 8mM
ALA) was injected intraperitoneally into each rat.
For PD, the D-Light system (Storzt) was used. A 300W xenon
short-arc lamp emitted blue light in the range from 375 to 440nm.
A foot pedal made it possible to switch between blue–violet
fluorescence excitation light and white light. In the endoscopic
eyepiece, a yellow long-pass filter reduces the reflected blue light,
intensifying the contrast between the red fluorescent and
nonfluorescent areas of the healthy surrounding tissue. Tumours
and premalignant lesions fluoresces bright red in the violet
excitation light.
Point spectroscopy is a highly sensitive method for measuring
fluorescence signals, making it a useful tool for in vivo
pharmacokinetic measurements. In this study, fluorescence emis-
sion spectra were recorded with an optical fibre-based spectro-
fluorometer based on a Peltier-cooled CCD coupled to a
spectrograph (Cromex 250, SI Instruments, Germany). Excitation
light (lex¼405nm) from a 75W high-pressure xenon lamp (UXL-
75 XE, Ushio Inc., Japan) was spectrally resolved by a quarter
metre monochromator (Chromex 250, SI Instruments, Germany)
with a bandwidth of 5nm and an excitation filter, SCHOTT BG3
(Schott AG, Mainz, Germany), mounted on a filter wheel. A stepper
motor (SMC 100, Princeton Instruments Inc., USA) controlled this
excitation filter wheel, which was equipped with different low-pass
filters to purify the excitation light. Excitation energy measured at
the distal end of the fibre tip was determined with a calibrated
power-metre (Optical Power Meter 840, Newport, USA). A filter
setup allows the acquisition of fluorescence emission spectra
between 455 and 900nm. The setup and data acquisition were
controlled by a 486 personal computer using CSMA software (SI
Instruments GmbH, Germany). An aqueous solution of rhodamine
B( c¼1 10
 6moll
 1) in a 10mm quartz cuvette was used as a
reference. Emission spectra of the reference were recorded before
and after each measurement. All measurements were normalised to
the peak value of the reference to give comparable results
corrected for day-to-day fluctuations in the excitation light energy
or detection pathway alignment. Point fluorescence measurements
of cancerous and normal tissue were performed with a 500mm
fibre probe. Each point measurement was repeated three times.
The peritoneal autofluorescence spectrum of a rat without any
medication was used as reference spectrum, and all data of the
spectrofluorometer presented in this work are the measured
fluorescence values after subtraction of the autofluorescence.
A total of 11 photosensitised rats were killed 2h after instillation
of ALA or HAL. A midline incision from the xyphoid process to
the symphysis pubis was made and the viscera were explored. To
avoid bleaching of the photosensitiser, all procedures were carried
out under dimmed room light.
The number of lesions in each photosensitised animal was
counted independently by two investigators, one performing
examination under white light and the other using fluorescence
diagnosis. Several biopsies were taken from fluorescent sites.
RESULTS
Metastases were most frequently found on the caudal side of the
diaphragm, the peritoneum, and less frequently on the omentum
and intestine. All biopsies taken from lesions seen by normal
inspection or detected through PD were histopathologically proven
cancer.
The number of metastases detected by the PD blue light mode
was significantly higher (w
2 test, Po0.01) than when using
standard white light abdominal inspection for all applied
concentrations (Table 1). About twice as many cancer lesions
were detected by PpIX fluorescence than by white light inspection.
Figure 1 shows a sequence of white light and blue light images of
small cancerous metastases through PD 2h following injection of
HAL (8mM), which would have been missed by standard white
light diagnosis.
A typical fluorescence spectrum registered by point spectro-
fluorometric measurement of a metastasis is shown in Figure 2. It
depicts the characteristic fluorescence emission spectrum of PpIX
and was the same independently on the used concentration or
precursor.
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sIn total, we measured 44 tumour sites and 44 normal tissue sites
in 11 rats. The mean values for each condition for tumour and
normal tissue are shown in Figure 3. Tumour to normal tissue
ratios for the fluorescence intensities ranged from 2.7 (4mM HAL)
to 10 for HAL at 8mM. The mean fluorescence intensities were
significantly different (Mann–Whitney U-test, Po0.01) between
normal and cancerous tissue for ALA and HAL. Increasing the
dosage of HAL from 8 to 12mM did not further increase the
fluorescence harvest.
At 8mM concentration, the hexyl-ester derivative produced
significantly higher PpIX fluorescence as compared to ALA
(Figure 3); however, visually the fluorescence contrast between
healthy and cancerous tissue was excellent for both the
compounds.
DISCUSSION
Owing to its good tumour selectivity and excellent clinical
tolerance, the photoactive precursor ALA is increasingly used as
photosensitiser in photodynamic therapy and fluorescence photo-
detection. 5-Aminolaevulinic acid can be applied topically (creams,
instillation) or systemically (oral, inhalation) (Peng et al, 1997). 5-
Aminolaevulinic acid-induced PpIX appears to be cleared from the
body within 24h of induction, whether the route is systemic or
topical (Webber et al, 1997). Systemic administration of doses
430mgkg
 1 resulted in a decrease of systolic blood pressure with
a median of 80mmHg 6–7h later. Lower doses did not affect the
haemodynamic variables (Heyerdahl et al, 1997; Webber et al,
1997). To date, no side effects have been reported following topical
application of ALA. Similarly, installation of up to 16mM HAL into
the bladder did not result in any side effects (Lange et al, 1999).
Gahlen et al (2001, 2002) have shown that local, intraperitoneal
photosensitisation with ALA is a more reliable and effective
method than systemic photosensitisation with ALA for detection of
small or occult peritoneal tumours. More lipophilic derivatives of
ALA, such as HAL, that have better bioavailability than ALA
should therefore show good performance in the detection of
micrometastases when given intraperitoneally.
To test HAL-induced fluorescence in vivo, we utilised the NuTu-
19 epithelial ovarian cancer animal model. This model closely
simulates clinical human ovarian cancer in terms of (a) method of
intraperitoneal spread, (b) formation of malignant ascites, and (c)
propensity for local metastases and organ invasion (omentum,
peritoneum, liver, spleen, bowel). Our previous experiments with
ALA tested time intervals between 0.5 and 4h at concentrations
between 4 and 20mM, and showed best discrimination between
healthy and cancerous tissue when 8mM ALA was applied for 2h
(Major et al, 1997, 2002a,b). We therefore compared ALA with
HAL at this dosage and time interval. At 8mM, intraperitoneal
application of HAL results in twice as much PpIX formation than
the same amount of ALA. These data confirm earlier reports of
Table 1 Numbers of metastases detected by white light and blue light
detection using HAL (4–12mM) and ALA (8mM)
Concentration (mM)
(number of animals) Precursor
Time after
injection (h)
White
light
Blue
light Ratio
4 (3) HAL 2.5 9 23 2.6
8 (4) HAL 2.0 70 123 1.8
12 (2) HAL 2.0 3 8 2.7
8 (2) ALA 2.0 10 16 1.6
Figure 1 Peritoneal metastases in blue and white light mode. Image (A)
shows a lesion that is only visible in the blue light mode, but not by white
light (position marked by a circle) (8mM HAL after 2h). Image (B) shows
three lesions visible by both blue and white light (big circle) and one only
detectable by fluorescence (small circle) (8mM HAL after 2h).
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Figure 2 Typical PpIX fluorescence spectrum of peritoneal ovarian
cancer metastasis 2h after i.p. administration of 8mM HAL.
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Figure 3 Mean fluorescence emission of healthy peritoneal (empty box)
and cancerous (grey box) tissue. Four different sites for normal tissue and
four sites of cancerous tissue were measured in each rat. In all, 8mM ALA
and 4–12mM HAL were applied and fluorescence was measured 2h after
injection (number of measurements/number of animals; bar¼s.d.).
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(Marti et al, 1999) and in vivo (Lange et al, 1999), and may permit,
in clinical use, shorter drug application time while retaining
tumour selectivity.
In our model, both HAL and its parent molecule effectively
detected small cancerous lesions. Half of these small tumours
would have been missed by normal inspection of the abdominal
cavity. We have demonstrated that HAL-induced fluorescence is a
convenient tool that improves the contrast of fluorescing
metastases against healthy tissue and allows the detection of
cancer lesions that would not have been discovered by normal
inspection. However, from our experiments, we cannot exclude
that the conditions of the experimental model used may not have
been optimal for HAL, and that varying experimental conditions,
such as incubation time with HAL or its delivery vehicle, might
further improve the selectivity of fluorescence localisation.
Photodiagnostic techniques such as HAL detection of occult
ovarian cancer tumours provide a platform technology that
permits minimally intrusive investigation, and could allow
detection by endoscopy and eventually elimination of ovarian
cancer cells at their earliest stages. Moreover, detection, diagnosis,
and treatment could be closely coupled, enabling effective
administration in a single, seamless process. To start with,
laparoscopic staging of early ovarian cancer would benefit from
this simple and straightforward method of photodetection.
Hexaminolaevulinate has greater potency to induce fluorescence
in cancerous lesions, and with the acquisition of further data on
safety in human, it may replace ALA in topical applications.
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